Abilify: Atypical Antipsychotic for Symptom Control and Stability
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.90 | $54.22 (0%) | 🛒 Add to cart |
| 90 | $0.78 | $81.33 $70.29 (14%) | 🛒 Add to cart |
| 180 | $0.66 | $162.66 $118.48 (27%) | 🛒 Add to cart |
| 270 | $0.62 | $243.99 $166.68 (32%) | 🛒 Add to cart |
| 360 | $0.60
Best per pill | $325.32 $214.87 (34%) | 🛒 Add to cart |
| Product dosage: 15mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.54 | $46.19 (0%) | 🛒 Add to cart |
| 60 | $1.09 | $92.37 $65.26 (29%) | 🛒 Add to cart |
| 90 | $0.94 | $138.56 $84.34 (39%) | 🛒 Add to cart |
| 120 | $0.85 | $184.75 $102.42 (45%) | 🛒 Add to cart |
| 180 | $0.79 | $277.12 $141.57 (49%) | 🛒 Add to cart |
| 270 | $0.74 | $415.69 $198.81 (52%) | 🛒 Add to cart |
| 360 | $0.71
Best per pill | $554.25 $254.03 (54%) | 🛒 Add to cart |
| Product dosage: 20mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.48 | $74.30 (0%) | 🛒 Add to cart |
| 60 | $1.76 | $148.60 $105.43 (29%) | 🛒 Add to cart |
| 90 | $1.52 | $222.90 $136.55 (39%) | 🛒 Add to cart |
| 120 | $1.39 | $297.21 $166.68 (44%) | 🛒 Add to cart |
| 180 | $1.27 | $445.81 $228.93 (49%) | 🛒 Add to cart |
| 270 | $1.19 | $668.71 $322.31 (52%) | 🛒 Add to cart |
| 360 | $1.15
Best per pill | $891.62 $414.68 (53%) | 🛒 Add to cart |
Synonyms | |||
Abilify (aripiprazole) is an atypical antipsychotic medication approved for the treatment of several psychiatric conditions, including schizophrenia, bipolar disorder, and as an adjunctive treatment for major depressive disorder. It functions as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and as an antagonist at serotonin 5-HT2A receptors, which contributes to its unique efficacy and tolerability profile. This mechanism helps stabilize dopamine and serotonin activity in the brain, reducing symptoms such as hallucinations, delusions, and mood swings while minimizing certain side effects commonly associated with first-generation antipsychotics.
Features
- Active ingredient: Aripiprazole
- Available in multiple formulations: oral tablets, orally disintegrating tablets, oral solution, and injectable forms
- Dosing flexibility with tablet strengths ranging from 2 mg to 30 mg
- Once-daily dosing for most indications
- Long-acting injectable (Abilify Maintena) available for monthly administration
- FDA-approved for use in adults and adolescents (13+ for schizophrenia, 10+ for bipolar mania)
Benefits
- Effective reduction of positive and negative symptoms in schizophrenia
- Mood stabilization in bipolar I disorder, reducing frequency of manic/mixed episodes
- Adjunctive efficacy in major depressive disorder when SSRIs provide inadequate response
- Lower risk of weight gain and metabolic side effects compared to some other atypical antipsychotics
- Flexible dosing options support individualized treatment plans
- Long-acting injectable formulation improves adherence and provides consistent drug levels
Common use
Abilify is commonly prescribed for the treatment of schizophrenia in adults and adolescents aged 13 years and older. It is also indicated for acute and maintenance treatment of manic and mixed episodes associated with bipolar I disorder in adults and pediatric patients 10 years and older. Additionally, it is used as adjunctive therapy to antidepressants for major depressive disorder in adults. Off-label uses may include irritability associated with autistic disorder (in pediatric patients), Tourette’s syndrome, and borderline personality disorder, though these applications require careful clinical consideration.
Dosage and direction
Dosage varies significantly based on indication, patient age, and clinical response. For schizophrenia in adults, the recommended starting dose is 10-15 mg once daily, with a target range of 10-30 mg daily. For bipolar mania, initial dosing typically begins at 15 mg once daily, with a maximum of 30 mg daily. As adjunctive treatment for depression, the starting dose is 2-5 mg daily, with titration based on response and tolerability. All formulations should be taken with or without food, at approximately the same time each day. The orally disintegrating tablet should be placed on the tongue without water. Long-acting injectable formulations require specific administration protocols by healthcare professionals.
Precautions
Patients should be monitored for suicidal thoughts and behaviors, particularly during initial treatment and dosage adjustments. Regular assessment of weight, blood glucose, and lipid profiles is recommended due to potential metabolic effects. Caution is advised when prescribing to elderly patients with dementia-related psychosis due to increased mortality risk. Patients should avoid alcohol consumption and be cautioned about operating machinery until they know how Abilify affects them. Abrupt discontinuation should be avoided; gradual tapering is recommended under medical supervision.
Contraindications
Abilify is contraindicated in patients with known hypersensitivity to aripiprazole or any component of the formulation. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole) or strong CYP2D6 inhibitors (e.g., quinidine, fluoxetine, paroxetine) may require dosage adjustments. Use with caution in patients with cardiovascular disease, cerebrovascular disease, or conditions that predispose to hypotension. The injectable formulation is contraindicated in patients with known hypersensitivity to aristada or any component of the product.
Possible side effects
Common side effects (≥10%) include akathisia, headache, agitation, anxiety, insomnia, nausea, vomiting, constipation, and dizziness. Less frequent but potentially serious side effects include neuroleptic malignant syndrome (characterized by hyperpyrexia, muscle rigidity, altered mental status), tardive dyskinesia (involuntary movements), metabolic changes (weight gain, hyperglycemia, dyslipidemia), orthostatic hypotension, and seizures. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at increased risk of death, primarily from cardiovascular or infectious causes.
Drug interaction
Abilify undergoes hepatic metabolism primarily through CYP3A4 and CYP2D6 enzymes. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole) may double aripiprazole exposure, while strong CYP3A4 inducers (e.g., carbamazepine) may reduce exposure by approximately 70%. Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) may increase aripiprazole exposure by approximately 60%. Dosage adjustments are necessary when co-administered with these medications. Caution is advised when combining with other CNS depressants, antihypertensive medications, or drugs that prolong QTc interval.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is close to the time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not take double or extra doses to make up for a missed dose. For patients using the long-acting injectable formulation, contact the healthcare provider if an injection is missed to determine the appropriate course of action.
Overdose
Symptoms of overdose may include sedation, vomiting, hypotension, tachycardia, and in severe cases, altered mental status, seizures, or coma. There is no specific antidote for aripiprazole overdose. Management involves supportive care, including monitoring of vital signs and ECG, gastric lavage if presented early, and administration of activated charcoal. Cardiovascular monitoring should continue for several days due to the drug’s long half-life. In cases of severe extrapyramidal symptoms, anticholinergic medications may be considered.
Storage
Store at room temperature (15-30°C or 59-86°F) in a dry place protected from light and moisture. Keep the oral solution in the original bottle and do not freeze. Orally disintegrating tablets should remain in the blister package until immediately before use. Keep all medications out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Properly dispose of any unused medication according to local regulations.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Abilify is a prescription medication that should only be used under the supervision of a qualified healthcare professional. Individual response to medication may vary, and only a healthcare provider can determine the appropriate treatment based on a patient’s specific medical condition, history, and current medications. Patients should not initiate, discontinue, or change dosage without consulting their healthcare provider.
Reviews
Clinical studies demonstrate Abilify’s efficacy across multiple indications. In schizophrenia trials, aripiprazole showed significant improvement in PANSS scores compared to placebo. For bipolar mania, studies demonstrated improvement in Young Mania Rating Scale scores. As adjunctive therapy for depression, trials showed improved response rates when added to antidepressant therapy. Many clinicians note its favorable metabolic profile compared to other atypical antipsychotics, though individual patient responses vary. Long-term maintenance studies support its efficacy in preventing relapse in both schizophrenia and bipolar disorder. Patient-reported outcomes often mention improved quality of life and functional capacity, though some report side effects such as akathisia requiring dosage adjustment or adjunctive management.